Sabrina Heltz
About Sabrina Heltz
Sabrina Heltz, age 60, has served as an independent director of Viemed Healthcare, Inc. since November 4, 2020. She is an actuary by training (Associate of the Society of Actuaries; Member of the American Academy of Actuaries) with 31 years at Blue Cross and Blue Shield of Louisiana culminating as SVP/Chief Analytics Officer, followed by COO of Ochsner Health Network, and currently Senior Healthcare Advisor at Rule of Three (Ro3). She holds a B.S. in Mathematics and Computer Science from Nicholls State University and brings deep payer and provider operations expertise, value-based care design, and analytics leadership to the board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Blue Cross and Blue Shield of Louisiana (BCBSLA) | Actuary → SVP/Chief Actuary → SVP/Chief Analytics Officer | 31-year career; ended August 2016 | Led provider contracting and reimbursement; advanced data/analytics capabilities enabling value-based reimbursement and quality/care improvement programs; engaged in legislative and regulatory matters with testimony and regulatory advising . |
| Ochsner Health Network | Chief Operating Officer | August 2016 – July 2023 | Led strategy and operations to enable success in value‑based care contracts across Medicare and commercial plans . |
External Roles
| Organization | Role | Tenure | Focus/Notes |
|---|---|---|---|
| Rule of Three (Ro3) | Senior Healthcare Advisor | After July 2023 – present | Advises clients on healthcare strategy and operations, specializing in value‑based care payment programs . |
Board Governance
- Committee assignments: Chair, Corporate Governance & Nominating (CG&N); Member, Audit; Member, Compensation .
- Independence: Board determined Ms. Heltz is independent under NI 58‑101 and NASDAQ listing standards; a majority of the Board is independent .
- Board leadership: Independent Chairman; independent directors held executive sessions at each of the four regular 2024 board meetings (Jan, May, Aug, Nov) .
- Risk oversight: Audit Committee reviews related party transactions; CG&N oversees governance and cybersecurity; Compensation Committee evaluates compensation risk; management concluded policies do not create material adverse risk .
Attendance (FY2024)
| Name | Board Meetings | Audit Committee | Compensation Committee | CG&N Committee |
|---|---|---|---|---|
| Sabrina Heltz | 3/4 | N/A | 3/4 | 4/4 |
Fixed Compensation
| Component | Amount/Policy | Notes |
|---|---|---|
| Annual cash retainer (independent directors) | $92,000 | Standard cash fee for independent directors. |
| Committee chair/member fees | Audit: Chair $25,000; Member $7,625. Compensation: Chair $20,000; Member $7,000. CG&N: Chair $15,000; Member $7,000 . | Ms. Heltz served as CG&N Chair and member of Audit and Compensation . |
| Chairman of the Board fee (increment) | $15,000 (for Chairman; not applicable to Heltz) . | Reference point. |
| Ms. Heltz 2024 cash fees (actual) | $106,000 | Reflects actual fees paid in FY2024. |
Performance Compensation
| Award Type | Grant Value (2024) | Shares/Units | Vesting | Performance Metrics |
|---|---|---|---|---|
| RSUs (non‑employee director grant) | $115,001 | 15,732 RSUs outstanding as of 12/31/2024 | These RSUs will vest on August 20, 2025 | No specific performance metrics disclosed for director RSUs; time‑based vesting . |
| Deferral election (Non‑Employee Directors Deferred Compensation Plan) | Available under 2024 Omnibus Plan | Directors may elect to defer receipt of stock upon vesting on a grant‑by‑grant basis | Deferrals per plan terms | N/A. |
Note: Under the 2024 Omnibus Plan, awards can include RSUs, DSUs, options, restricted stock, SARs, and performance awards; plan amendments in 2025 added minimum one‑year vesting and clarified change‑in‑control treatment .
Other Directorships & Interlocks
| Person | Current Public Company Boards | Roles/Committees |
|---|---|---|
| Sabrina Heltz | None disclosed | No other reporting issuer directorships listed for Ms. Heltz; only Mr. Kaushal disclosed external public boards . |
Expertise & Qualifications
- Actuarial and analytics leadership across payer and provider domains; credentials include Associate in the Society of Actuaries and Member of the American Academy of Actuaries .
- Value‑based care design, provider contracting, reimbursement strategy, and regulatory engagement experience .
- Financial literacy and independence suitable for Audit, Compensation, and CG&N committee service; Audit Committee members are independent and financially literate under NI 52‑110 .
Equity Ownership
| Holder | Beneficial Ownership (Shares) | % of Outstanding | Pledged Shares | Derivative/Equity Awards Outstanding |
|---|---|---|---|---|
| Sabrina Heltz | 51,759 | <1% (based on 39,523,787 shares) | None pledged | 15,732 RSUs outstanding as of 12/31/2024 (vesting 8/20/2025); no options outstanding . |
Insider Trades & Compliance
| Item | Disclosure | Notes |
|---|---|---|
| Related‑party transactions | None involving directors/officers above $120,000 since 1/1/2024 . | Audit Committee must approve any related‑party transactions; none reported . |
| Section 16(a) filings | One late Form 4 reported for Dr. Frazier; no other directors/officers noted as delinquent . | No late filing indication for Ms. Heltz . |
| Hedging/pledging policy | Prohibits short‑term trading, short sales, options trading, trading on margin, pledging, and hedging . | Applies to directors, officers, employees, consultants . |
Governance Assessment
- Strengths: Independent status; multi‑committee engagement with CG&N chair role; robust governance and cybersecurity oversight through CG&N; prohibition of hedging/pledging; no related‑party transactions or delinquent filings reported for Heltz; equity grants support alignment via RSUs .
- Engagement: 100% CG&N attendance; 75% Board and Compensation attendance in 2024; Audit attendance not listed (N/A), which may reflect mid‑year committee changes or role timing; continued monitoring of attendance advisable for Board effectiveness .
- Compensation alignment: For 2024, her equity award ($115,001) was comparable to cash fees ($106,000), indicating meaningful equity mix for alignment; directors can further align via deferral elections under the plan .
- Conflicts/Red Flags: No material related‑party transactions; no share pledging; no reported Section 16(a) delinquency for Heltz; no other public company directorships disclosed that could create interlocks. Attendance below full participation at Board and Compensation (3/4 each) is a minor watch item but not a material red flag in context of full CG&N participation .
RED FLAGS: None disclosed related to conflicts, related‑party transactions, hedging/pledging, or delinquent filings; attendance short of 100% at Board and Compensation in 2024 (3/4 each) should be monitored as a soft governance indicator .